{
    "symbol": "BIOR",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-14 20:04:12",
    "content": " To summarize some of our anticipated upcoming milestones for both platforms: we plan to initiate a tox study with PGN-600 after we obtain final feedback from the FDA on our study protocols later this year, nd based on the results intend to file an IND in Q1 2023 to support the initiation of our phase 1 study; we expect to start having interim data around mid next year and to complete the study by Q3 '23; we're continuing to optimize our next generation systemic therapeutics device to support additional preclinical data generation by Q1 '23; and based on the additional data, we expect to expand our collaborations during the remainder of 2023; finally, we expect to initiate our phase 2 trial for PGM-600 after completion of phase 1 next year."
}